Okay, let's tackle this question. The question is about which drug to use in a CML patient with the T315I mutation. First, I need to recall the core concept here. CML is a myeloproliferative disorder caused by the Philadelphia chromosome, which leads to the BCR-ABL fusion protein. The standard treatment for CML is tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, nilotinib, etc. However, mutations in the BCR-ABL kinase domain can confer resistance to these drugs.

Now, the T315I mutation specifically. I remember that some TKIs are effective against certain mutations. The T315I is a gatekeeper mutation, which is known to confer resistance to most first and second-line TKIs. So, the drugs that are effective against this mutation would be the third-line agents. I think ponatinib is the one that works here. Let me check: Ponatinib is a third-generation TKI that's active against the T315I mutation. Other options like bosutinib might also be considered, but ponatinib is the key one.

Looking at the options, the correct answer would be ponatinib. Now, the other options: Imatinib, dasatinib, nilotinib are first or second-gen and don't work against T315I. So the incorrect options would be the other TKIs. The clinical pearl here is that T315I is a gatekeeper mutation, and ponatinib is the go-to drug for that. Also, remember that this mutation is a major resistance mechanism, so it's important to test for it and choose the right drug.

**Core Concept**
Chronic myeloid leukemia (CML) is driven by the BCR-ABL tyrosine kinase fusion protein. Resistance to tyrosine kinase inhibitors (TKIs) often arises from mutations in the ABL kinase domain, such as the **T315I gatekeeper mutation**, which disrupts drug binding. Third-generation TKIs overcome this resistance.

**Why the Correct Answer is Right**
**Ponatinib** is a third-generation TKI with high affinity for the T315I-mutant BCR-ABL. It binds to the ABL kinase domain regardless of conformational changes caused by mutations. This makes it effective in CML patients with T315I, where first/second-generation TKIs like imatinib, dasatinib, or nilotinib fail due to steric hindrance from the bulkier isoleucine at position 315.

**Why Each Wrong Option is Incorrect**
**Option A: Imatinib** – First-generation TKI; T315I mutation creates a steric barrier preventing imatinib binding.
**Option B: Dasatinib** – Second-generation TKI; also blocked by T315I due to reduced hydrophobic interactions.
**Option C: Nilotinib** – Second-generation TKI; ineffective against T315I due to similar binding pocket constraints.

**Clinical Pearl / High-Yield Fact**
**T315I is the "gatekeeper" mutation** – it is the most clinically significant resistance mutation in CML. Remember that

✓ Correct Answer: D. Ponatinib